ABBOTT INDIA
Quarterly Results Analysis [Dec2023]
ABBOTT INDIA Quarterly Results
Standalone | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,437 Cr | ₹1,494 Cr | ₹1,479 Cr | ₹1,343 Cr | ₹1,322 Cr | ₹1,379 Cr | ₹1,304 Cr | ₹1,255 Cr |
Expenses | ₹1,049 Cr | ₹1,113 Cr | ₹1,124 Cr | ₹1,063 Cr | ₹1,010 Cr | ₹1,036 Cr | ₹1,034 Cr | ₹961 Cr |
Operating Income | ₹388 Cr | ₹381 Cr | ₹355 Cr | ₹280 Cr | ₹312 Cr | ₹343 Cr | ₹270 Cr | ₹294 Cr |
Other Income | ₹56 Cr | ₹56 Cr | ₹56 Cr | ₹50 Cr | ₹44 Cr | ₹34 Cr | ₹27 Cr | ₹21 Cr |
Interest | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr |
Depreciation | ₹18 Cr | ₹18 Cr | ₹17 Cr | ₹17 Cr | ₹18 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr |
Profit Before Tax | ₹422 Cr | ₹415 Cr | ₹390 Cr | ₹308 Cr | ₹335 Cr | ₹355 Cr | ₹275 Cr | ₹292 Cr |
Profit After Tax | ₹311 Cr | ₹313 Cr | ₹290 Cr | ₹231 Cr | ₹247 Cr | ₹266 Cr | ₹206 Cr | ₹211 Cr |
EPS | ₹146.34 | ₹147.27 | ₹136.58 | ₹108.90 | ₹116.16 | ₹124.95 | ₹96.77 | ₹99.49 |
Industry Peers & Returns | 1W | 1M | 1Y |
ABBOTT INDIA | -5.6% | -6.9% | 27.4% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
ABBOTT INDIA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -3.81 % |
Y-o-Y | 8.69 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹1,437 Cr | -3.81 | |
Sep2023 | ₹1,494 Cr | 1.02 | |
Jun2023 | ₹1,479 Cr | 10.12 | |
Mar2023 | ₹1,343 Cr | 1.58 | |
Dec2022 | ₹1,322 Cr | -4.14 | |
Sep2022 | ₹1,379 Cr | 5.77 | |
Jun2022 | ₹1,304 Cr | 3.93 | |
Mar2022 | ₹1,255 Cr | - |
ABBOTT INDIA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 1.79 % |
Y-o-Y | 24.18 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹388 Cr | 1.79 | |
Sep2023 | ₹381 Cr | 7.29 | |
Jun2023 | ₹355 Cr | 26.73 | |
Mar2023 | ₹280 Cr | -10.28 | |
Dec2022 | ₹312 Cr | -9.02 | |
Sep2022 | ₹343 Cr | 27.02 | |
Jun2022 | ₹270 Cr | -7.97 | |
Mar2022 | ₹294 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 5.85 % |
Y-o-Y | 14.27 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 26.98% | 5.85 | |
Sep2023 | 25.49% | 6.21 | |
Jun2023 | 24% | 15.05 | |
Mar2023 | 20.86% | -11.65 | |
Dec2022 | 23.61% | -5.10 | |
Sep2022 | 24.88% | 20.08 | |
Jun2022 | 20.72% | -11.45 | |
Mar2022 | 23.4% | - |
ABBOTT INDIA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -0.63 % |
Y-o-Y | 25.99 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹311 Cr | -0.63 | |
Sep2023 | ₹313 Cr | 7.82 | |
Jun2023 | ₹290 Cr | 25.42 | |
Mar2023 | ₹231 Cr | -6.24 | |
Dec2022 | ₹247 Cr | -7.04 | |
Sep2022 | ₹266 Cr | 29.12 | |
Jun2022 | ₹206 Cr | -2.73 | |
Mar2022 | ₹211 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 3.34 % |
Y-o-Y | 15.91 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 21.64 % | 3.34 | |
Sep2023 | 20.94 % | 6.73 | |
Jun2023 | 19.62 % | 13.87 | |
Mar2023 | 17.23 % | -7.71 | |
Dec2022 | 18.67 % | -3.01 | |
Sep2022 | 19.25 % | 22.07 | |
Jun2022 | 15.77 % | -6.41 | |
Mar2022 | 16.85 % | - |
ABBOTT INDIA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -0.63 % |
Y-o-Y | 25.98 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹146.34 | -0.63 | |
Sep2023 | ₹147.27 | 7.83 | |
Jun2023 | ₹136.58 | 25.42 | |
Mar2023 | ₹108.9 | -6.25 | |
Dec2022 | ₹116.16 | -7.03 | |
Sep2022 | ₹124.95 | 29.12 | |
Jun2022 | ₹96.77 | -2.73 | |
Mar2022 | ₹99.49 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD